CL-387,785 (BioDeep_00000774447)

   


代谢物信息卡片


N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide

化学式: C18H13BrN4O (380.0272668)
中文名称: N-[4-[(3-溴苯基)氨基]-6-喹唑啉基]-2-丁炔酰胺
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC#CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br
InChI: InChI=1S/C18H13BrN4O/c1-2-4-17(24)22-14-7-8-16-15(10-14)18(21-11-20-16)23-13-6-3-5-12(19)9-13/h3,5-11H,1H3,(H,22,24)(H,20,21,23)

描述信息

D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

同义名列表

2 个代谢物同义名

N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CL-387,785



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Yong Cai, Zhaoying Sheng, Zhiyi Dong, Jiying Wang. EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma. Current molecular pharmacology. 2023; 16(2):211-216. doi: 10.2174/1874467215666220329212300. [PMID: 35352671]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Daniela A Eisinger, Hermann Ammer. Epidermal growth factor treatment switches δ-opioid receptor-stimulated extracellular signal-regulated kinases 1 and 2 signaling from an epidermal growth factor to an insulin-like growth factor-1 receptor-dependent mechanism. Molecular pharmacology. 2011 Feb; 79(2):326-35. doi: 10.1124/mol.110.064956. [PMID: 21078885]
  • Vicente E Torres, William E Sweeney, Xiaofang Wang, Qi Qian, Peter C Harris, Philip Frost, Ellis D Avner. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney international. 2004 Nov; 66(5):1766-73. doi: 10.1111/j.1523-1755.2004.00952.x. [PMID: 15496147]
  • Vicente E Torres, William E Sweeney, Xiaofang Wang, Qi Qian, Peter C Harris, Philip Frost, Ellis D Avner. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney international. 2003 Nov; 64(5):1573-9. doi: 10.1046/j.1523-1755.2003.00256.x. [PMID: 14531789]
  • Carmela Marfella-Scivittaro, Andrea Quiñones, Stephanie A Orellana. cAMP-dependent protein kinase and proliferation differ in normal and polycystic kidney epithelia. American journal of physiology. Cell physiology. 2002 Apr; 282(4):C693-707. doi: 10.1152/ajpcell.00122.2001. [PMID: 11880258]
  • W E Sweeney, Y Chen, K Nakanishi, P Frost, E D Avner. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney international. 2000 Jan; 57(1):33-40. doi: 10.1046/j.1523-1755.2000.00829.x. [PMID: 10620185]
  • W E Sweeney, L Futey, P Frost, E D Avner. In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor. Kidney international. 1999 Aug; 56(2):406-13. doi: 10.1046/j.1523-1755.1999.00577.x. [PMID: 10432378]